Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. STKE, 4 September 2001
Vol. 2001, Issue 98, p. tw6
[DOI: 10.1126/stke.2001.98.tw6]

EDITORS' CHOICE

Diabetes Aspirin for Diabetics

Resistance of cells to the actions of insulin is a prominent feature of type 2 diabetes. As early as 1876, reports emerged that high doses of aspirin could help decrease concentrations of glucose in the blood of diabetic patients, an action that could reflect enhanced insulin action in target cells. Yuan et al. are finally able to provide a mechanism that may explain this effect. Their studies show that aspirin in high doses inhibits the protein kinase IKKβ, which mediates the actions of pro-inflamatory cytokines. Furthermore, heterozygous mice that had lost one allele encoding IKKβ were protected against insulin resistance when fed a high-fat diet. Thus, IKKβ may be a useful target for therapeutic agents designed to ameliorate insulin resistance.

M. Yuan, N. Konstantopoulos, J. Lee, L. Hansen, Z.-W. Li, M. Karin, S. E. Shoelson, Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 293, 1673-1677. [Abstract] [Full Text]

Citation: Aspirin for Diabetics. Sci. STKE 2001, tw6 (2001).


To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882